Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future

/PRNewswire/ -- Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross profit amounted to RMB738.5 million Adjusted...

Related Keywords

France ,Taiwan ,Dubai ,Dubayy ,United Arab Emirates ,Germany ,Switzerland ,Zhejiang ,China ,Chengdu ,Sichuan ,Australia ,Suzhou ,Jiangsu ,Zhoupu ,Hangzhou ,Japan ,Canada ,Qiantang ,Guangdong ,United States ,United Kingdom ,Taizhou ,Shanghai ,Jiaxing ,Chinese ,America ,Ningbo Nuobai ,Chen Cheney Mao ,Langhua Pharma ,Investment Corporation Of Dubai ,Viva Biotech Holdings ,Shanghai Supercomputing Center ,Temasek ,Successful Exits Of Certain Incubation Portfolio Companies ,Viva Biotech Holdings Group ,Langhua Pharmaceuticals ,Annual Results ,Highlight Capital ,True Light Capital ,Investment Corporation ,Reporting Period ,Attractive Outlook ,Long Run Despite Slight Fluctuation ,Chinese Mainland ,Langhua Pharmaceutical ,Certain Incubation Portfolio Companies ,Future Plans ,Incubation Business ,North America ,Active Pharmaceutical Ingredient ,Shanghai Supercomputing ,Faladi Road ,Qiantang New District ,Supercomputing Center ,Viva Biotech ,